KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease KT-621 demonstrated strong degradation of STAT6 in human ...
Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.
Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...
Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high ...
Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...
News Medical on MSN5d
Childhood adversity linked to elevated health risks, differing by sex and stressResearchers assess the heterogeneous effects of childhood adversity on disease biomarkers and health conditions in adulthood.
SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’Topline safety data of SB101 Phase 1 study expected ...
DeepCure to Present In Vivo Efficacy and Safety Data of BRD4 (BD2) Inhibitor DC-9476 for Macrophage Activation Syndrome at EMBO Conference ...
The Key To Old Age Long seen as a fatality or the mere expression of the accumulation of oxidation and genetic damage, aging is increasingly understood as a biological program called senescence, ...
Osteoarthritis (OA) is the most common arthritis worldwide, causing pain, disability, and loss of function due to chronic joint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback